Effective suppression of tumour cells by oligoclonal HER2-targeted delivery of liposomal doxorubicin

References

• Amselem, S., Gabizon, A., and Barenholz, Y., 1990. Optimization and upscaling of doxorubicin‐containing liposomes for clinical use. Journal of pharmaceutical sciences, 79, 1045–1052.
   PubMed Web of Science ®Google Scholar
• Baneyx, F., and Mujacic, M., 2004. Recombinant protein folding and misfolding in Escherichia coli. Nature biotechnology, 22, 1399–1408.
   PubMed Web of Science ®Google Scholar
• Barenholz, Y., 2001. Liposome application: problems and prospects. Current opinion in colloid & interface science, 6, 66–77.
   Web of Science ®Google Scholar
• Ben-Kasus, T., et al., 2009. Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: relevance of receptor endocytosis. Proceedings of the national academy of sciences, 106, 3294–3299.
   PubMed Web of Science ®Google Scholar
• Bradford, M.M., 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Analytical biochemistry, 72, 248–254.
   PubMed Web of Science ®Google Scholar
• Bulbake, U., et al., 2017. Liposomal formulations in clinical use: an updated review. Pharmaceutics, 9, 12.
   PubMed Web of Science ®Google Scholar
• Chen, J., et al., 2016. Nanobody medicated immunoassay for ultrasensitive detection of cancer biomarker alpha-fetoprotein. Talanta, 147, 523–530.
   PubMed Web of Science ®Google Scholar
• Clark, E.D.B., 2001. Protein refolding for industrial processes. Current opinion in biotechnology, 12, 202–207.
   PubMed Web of Science ®Google Scholar
• Cortez‐Retamozo, V., et al., 2002. Efficient tumor targeting by single‐domain antibody fragments of camels. International journal of cancer, 98, 456–462.,
   PubMed Web of Science ®Google Scholar
• Csuhai, E., et al., 2015. Determination of key parameters for a mechanism‐based model to predict doxorubicin release from actively loaded liposomes. Journal of pharmaceutical sciences, 104, 1087–1098.
   PubMed Web of Science ®Google Scholar
• Deamer, D.W., and Bramhall, J., 1986. Permeability of lipid bilayers to water and ionic solutes. Chemistry and physics of lipids, 40, 167–188.
   PubMed Web of Science ®Google Scholar
• Djender, S., et al., 2014. Bacterial cytoplasm as an effective cell compartment for producing functional VHH-based affinity reagents and Camelidae IgG-like recombinant antibodies. Microbial cell factories, 13, 140.
   PubMed Web of Science ®Google Scholar
• Drebin, J., Link, V., and Greene, M., 1988. Monoclonal antibodies specific for the neu oncogene product directly mediate anti-tumor effects in vivo. Oncogene, 2, 387–394.
   PubMed Web of Science ®Google Scholar
• Emde, A., Köstler, W.J., and Yarden, Y., 2012. Therapeutic strategies and mechanisms of tumorigenesis of HER2-overexpressing breast cancer. Critical reviews in oncology/hematology, 84, e49–e57.
   PubMed Web of Science ®Google Scholar
• Engvall, E., 1980. Enzyme immunoassay ELISA and EMIT. Methods in enzymology, 70, 419–439.
   PubMedGoogle Scholar
• Farajpour, Z., et al., 2014. A nanobody directed to a functional epitope on VEGF, as a novel strategy for cancer treatment. Biochemical and biophysical research communications, 446, 132–136.
   PubMed Web of Science ®Google Scholar
• Farasat, A., et al., 2017. Affinity enhancement of nanobody binding to EGFR: in silico site-directed mutagenesis and molecular dynamics simulation approaches. Journal of biomolecular structure and dynamics, 35, 1710–1728.
   PubMed Web of Science ®Google Scholar
• Fritze, A., et al., 2006. Remote loading of doxorubicin into liposomes driven by a transmembrane phosphate gradient. Biochimica et biophysica acta (BBA)-biomembranes, 1758, 1633–1640.
   PubMed Web of Science ®Google Scholar
• Gabizon, A., Shmeeda, H., and Barenholz, Y., 2003. Pharmacokinetics of pegylated liposomal doxorubicin. Clinical pharmacokinetics, 42, 419–436.
   PubMed Web of Science ®Google Scholar
• Ganta, S., et al., 2008. A review of stimuli-responsive nanocarriers for drug and gene delivery. Journal of controlled release, 126, 187–204.
   PubMed Web of Science ®Google Scholar
• Gao, J., et al., 2009. Tumor-targeted PE38KDEL delivery via PEGylated anti-HER2 immunoliposomes. International journal of pharmaceutics, 374, 145–152.
   PubMed Web of Science ®Google Scholar
• Hathaway, H.J., et al., 2011. Detection of breast cancer cells using targeted magnetic nanoparticles and ultra-sensitive magnetic field sensors. Breast cancer research, 13, R108.
   PubMed Web of Science ®Google Scholar
• Jamnani, F.R., et al., 2012. Targeting high affinity and epitope-distinct oligoclonal nanobodies to HER2 over-expressing tumor cells. Experimental cell research, 318, 1112–1124.
   PubMed Web of Science ®Google Scholar
• Kasprzyk, P.G., et al., 1992. Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies. Cancer research, 52, 2771–2776.
   PubMed Web of Science ®Google Scholar
• Kirpotin, D., et al., 1997. Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro. Biochemistry, 36, 66–75.
   PubMed Web of Science ®Google Scholar
• Kolkman, J.A., and Law, D.A., 2010. Nanobodies–from llamas to therapeutic proteins. Drug discovery today: technologies, 7, e139–e146.
   Google Scholar
• Laemmli, U.K., 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 227, 680–685.
   PubMed Web of Science ®Google Scholar
• Luo, R., et al., 2017. Distinct biodistribution of doxorubicin and the altered dispositions mediated by different liposomal formulations. International journal of pharmaceutics, 519, 1–10.
   PubMed Web of Science ®Google Scholar
• Makino, T., et al., 2011. Comprehensive engineering of Escherichia coli for enhanced expression of IgG antibodies. Metabolic engineering, 13, 241–251.
   PubMed Web of Science ®Google Scholar
• Mao, H.-Q., et al., 2001. Chitosan-DNA nanoparticles as gene carriers: synthesis, characterization and transfection efficiency. Journal of controlled release, 70, 399–421.
   PubMed Web of Science ®Google Scholar
• Mehn, D., et al., 2017. Analytical ultracentrifugation for analysis of doxorubicin loaded liposomes. International journal of pharmaceutics, 523, 320–326.
   PubMed Web of Science ®Google Scholar
• Mi, L., et al., 2016. A novel photoelectrochemical immunosensor by integration of nanobody and TiO 2 nanotubes for sensitive detection of serum cystatin C. Analytica chimica acta, 902, 107–114.
   PubMed Web of Science ®Google Scholar
• Mosmann, T., 1983. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. Journal of immunological methods, 65, 55–63.
   PubMed Web of Science ®Google Scholar
• Niu, G., Cogburn, B., and Hughes, J., 2010. Preparation and characterization of doxorubicin liposomes. Cancer nanotechnology: methods and protocols, 624, 211–219.
   Google Scholar
• Nuciforo, P., et al., 2016. High HER2 protein levels correlate with increased survival in breast cancer patients treated with anti-HER2 therapy. Molecular oncology, 10, 138–147.
   PubMed Web of Science ®Google Scholar
• Ogawara, K.-I., et al., 2009. In vivo anti-tumor effect of PEG liposomal doxorubicin (DOX) in DOX-resistant tumor-bearing mice: Involvement of cytotoxic effect on vascular endothelial cells. Journal of controlled release, 133, 4–10.
   PubMed Web of Science ®Google Scholar
• Park, J.W., 2002. Liposome-based drug delivery in breast cancer treatment. Breast cancer research: BCR, 4, 95
   PubMed Web of Science ®Google Scholar
• Park, J.W., Benz, C.C., and Martin, F.J., 2004. Future directions of liposome-and immunoliposome-based cancer therapeuticsed. Seminars in oncology, 31(6 Suppl 13), 196–205.
   Web of Science ®Google Scholar
• Pruszynski, M., et al., 2014. Improved tumor targeting of anti-HER2 nanobody through N-succinimidyl 4-guanidinomethyl-3-iodobenzoate radiolabeling. Journal of nuclear medicine, 55, 650–656.
   PubMed Web of Science ®Google Scholar
• Rahbarizadeh, F., et al., 2006. Over expression of anti-MUC1 single-domain antibody fragments in the yeast Pichia pastoris. Molecular immunology, 43, 426–435.,
   PubMed Web of Science ®Google Scholar
• Rubin, I., and Yarden, Y., 2001. The basic biology of HER2. Annals of oncology, 12, S3–S8.
   PubMed Web of Science ®Google Scholar
• Sabeti, B., et al., 2014. Development and characterization of liposomal doxorubicin hydrochloride with palm oil. BioMed research international, 2014,
   PubMedGoogle Scholar
• Sambrook, J., and Russell, D., 2001. Molecular cloning: a laboratory manual. 2001. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press.
   Google Scholar
• Shargh, V.H., Hondermarck, H., and Liang, M., 2016. Antibody-targeted biodegradable nanoparticles for cancer therapy. Nanomedicine, 11, 63–79.
   PubMed Web of Science ®Google Scholar
• Silverman, L., and Barenholz, Y., 2015. In vitro experiments showing enhanced release of doxorubicin from Doxil® in the presence of ammonia may explain drug release at tumor site. Nanomedicine: nanotechnology, biology and medicine, 11, 1841–1850.
   PubMed Web of Science ®Google Scholar
• Stewart, J.C.M., 1980. Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Analytical biochemistry, 104, 10–14.
   PubMed Web of Science ®Google Scholar
• Vaneycken, I., et al., 2011. Preclinical screening of anti-HER2 nanobodies for molecular imaging of breast cancer. FASEB journal: official publication of the federation of American societies for experimental biology, 25, 2433–2446.
   PubMed Web of Science ®Google Scholar
• Vingerhoeds, M., et al., 1996. Immunoliposome-mediated targeting of doxorubicin to human ovarian carcinoma in vitro and in vivo. British journal of cancer, 74, 1023.
   PubMed Web of Science ®Google Scholar
• Wahler, J., and Suh, N., 2015. Targeting HER2 positive breast cancer with chemopreventive agents. Current pharmacology reports, 1, 324–335.
   PubMedGoogle Scholar
• Working, P., and Dayan, A., 1996. Pharmacological-toxicological expert report. CAELYX (Stealth liposomal doxorubicin HCl). Human & experimental toxicology, 15, 751–785.
   PubMed Web of Science ®Google Scholar
• Yang, T., et al., 2007. Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. Journal of controlled release, 120, 169–177.
   PubMed Web of Science ®Google Scholar
• Zucker, D., et al., 2009. Liposome drugs' loading efficiency: a working model based on loading conditions and drug's physicochemical properties. Journal of controlled release, 139, 73–80.
   PubMed Web of Science ®Google Scholar